Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Benzinga · 3d ago
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.